Glutathione based approaches to improving cancer treatment

被引:25
作者
Kauvar, LM
Morgan, AS
Sanderson, PE
Henner, WD
机构
[1] Terrapin Technol, San Francisco, CA 94080 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
关键词
cancer; glutathione; drugs;
D O I
10.1016/S0009-2797(97)00163-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of cytotoxic chemotherapy for cancer therapy has been very successful in the treatment and often cure of patients with particular neoplasms, such as testicular carcinomas and some lymphomas. In addition, the use of adjuvant chemotherapy in patients whose primary tumor has been surgically removed contributes significantly to cure rates in some of the more common malignancies such as breast carcinoma and colon cancer. Nonetheless, for most patients with metastatic malignancies, current antineoplastic drugs provide only brief remissions with few or no long term cures. In addition, the side effects of therapy lead to substantial morbidity in nearly all patients. Insights derived from model system studies on two glutathione based lead compounds, TER286 and TER199, suggest new clinical strategies and raise interesting basic research questions regarding the cell biology foundations of cancer chemotherapy. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:225 / 238
页数:14
相关论文
共 38 条
[1]  
AliOsman F, 1997, J BIOL CHEM, V272, P10004
[2]   SEPARATION OF OXIDANT-INITIATED AND REDOX-REGULATED STEPS IN THE NF-KAPPA-B SIGNAL-TRANSDUCTION PATHWAY [J].
ANDERSON, MT ;
STAAL, FJT ;
GITLER, C ;
HERZENBERG, LA ;
HERZENBERG, LA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) :11527-11531
[3]  
BAILES JS, 1995, CANCER, V76, P1886, DOI 10.1002/1097-0142(19951115)76:10+<1886::AID-CNCR2820761304>3.0.CO
[4]  
2-Q
[5]  
Ban N, 1996, CANCER RES, V56, P3577
[6]   ADJUVANT THERAPY FOR STAGE-III COLON-CANCER - ECONOMICS RETURNS TO RESEARCH AND COST-EFFECTIVENESS OF TREATMENT [J].
BROWN, ML ;
NAYFIELD, SG ;
SHIBLEY, LM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) :424-430
[7]  
Broxmeyer H. E., 1996, Blood, V88, p594A
[8]   IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CLINICAL ONCOLOGY [J].
CHANG, FJ ;
SYRJANEN, S ;
SYRJANEN, K .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :1009-1022
[9]  
CIACCIO PJ, 1995, MOL PHARMACOL, V48, P639
[10]   REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
CRAWFORD, J ;
OZER, H ;
STOLLER, R ;
JOHNSON, D ;
LYMAN, G ;
TABBARA, I ;
KRIS, M ;
GROUS, J ;
PICOZZI, V ;
RAUSCH, G ;
SMITH, R ;
GRADISHAR, W ;
YAHANDA, A ;
VINCENT, M ;
STEWART, M ;
GLASPY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170